Global market leader in biosimilars and generic drugs is Sandoz. Our goal as a division of the Novartis Group is to find fresh approaches to enhancing and extending people’s lives. By developing cutting-edge methods to make high-quality medicine more widely available, we help society meet the growing demand for healthcare. Our portfolio of about 1000 compounds, which spans all key therapeutic categories, was responsible for US$10.1 billion in sales in 2016. Our goods reached well over 500 million patients in 2016 and we hope to reach one billion by the end of the year. Near Germany’s Greater Munich region, in Holzkirchen, is where Sandoz is headquartered.
